"1"^^ . "2" . . . "RIV/00216208:11150/14:10218516!RIV15-MSM-11150___" . . . . "duloxetine; SSRI; TCA; diabetic neuropathy; dementia; psychotherapy; diabetes; depression"@en . . "I" . "Deprese a diabetes"@cs . "[F8C5EFF6F317]" . "CZ - \u010Cesk\u00E1 republika" . . "Deprese a diabetes" . . "10295" . . . . "Remedia" . "24" . . "T\u016Fma, Ivan" . "0862-8947" . "Epidemiologic studies have documented an increased prevalence of depression in patients with diabetes. The pathogenesis of depression in diabetes is complex. The adverse life events, course and severity of diabetes, neuroendocrine and neuroimmune changes, genetic and personality factors are all likely contributors to its occurrence. The patients with diabetes are at higher risk of developing depression in comparison with healthy persons and depression may increase the risk of developing Type 2 diabetes. Combination of diabetes and depression could substantially increase the risk of mortality. Depression and diabetes are associated with a significantly increased risk of coronary heart disease. Both depression and diabetes independently increase the risk of dementia. Complex treatment of the patients with diabetes and comorbid depression comprises psychological support and pharmacological treatment. Tricyclic antidepressants are not a first choice drug because of their antimuscarinic side effects, mainly cardiotoxicity. Selective serotonin reuptake inhibitors as well as venlafaxine and trazodone are effective in the treatment of depressive symptoms in diabetes. Antidepressant duloxetine is registered for the treatment of neuropathic pain. However long-term use of antidepressants can increase the risk of developing type 2 diabetes."@en . "5"^^ . . "Deprese a diabetes"@cs . "Epidemiologick\u00E9 studie prok\u00E1zaly, \u017Ee nemocn\u00ED s diabetem maj\u00ED zv\u00FD\u0161enou prevalenci deprese. Patogeneze deprese p\u0159i diabetu je komplexn\u00ED a zahrnuje celou \u0161k\u00E1lu p\u0159\u00ED\u010Din. Pod\u00EDlej\u00ED se na n\u00ED negativn\u00ED \u017Eivotn\u00ED ud\u00E1losti, pr\u016Fb\u011Bh a komplikace diabetu, neuroendokrinn\u00ED a neuroimunitn\u00ED zm\u011Bny, genetick\u00E9 a osobnostn\u00ED faktory. Riziko vzniku deprese u nemocn\u00FDch s diabetem mellitem je v\u011Bt\u0161\u00ED v porovn\u00E1n\u00ED se zdrav\u00FDmi lidmi, a naopak deprese m\u016F\u017Ee zvy\u0161ovat riziko rozvoje diabetu 2. typu. Kombinace diabetu a deprese m\u016F\u017Ee stup\u0148ovat riziko mortality. S depres\u00ED a diabetem tak\u00E9 souvis\u00ED v\u00FDznamn\u011B zv\u00FD\u0161en\u00E9 riziko vzniku kardiovaskul\u00E1rn\u00EDch i cerebrovaskul\u00E1rn\u00EDch poruch a demenc\u00ED. Systematick\u00E1 p\u00E9\u010De o pacienty s diabetem a depres\u00ED mus\u00ED b\u00FDt komplexn\u00ED a m\u011Bla by zahrnovat psychologickou podporu i farmakologickou l\u00E9\u010Dbu. Zvolen\u00E1 farmakologick\u00E1 l\u00E9\u010Dba by zejm\u00E9na nem\u011Bla zhor\u0161ovat kompenzaci diabetu ne\u017E\u00E1douc\u00EDmi metabolick\u00FDmi d\u016Fsledky. Vhodn\u00E1 jsou psychofarmaka ze skupiny SSRI, d\u00E1le venlafaxin a trazodon. V l\u00E9\u010Db\u011B diabetick\u00FDch pacient\u016F s depres\u00ED nepat\u0159\u00ED mezi l\u00E9ky volby tricyklick\u00E1 antidepresiva. Jejich pod\u00E1v\u00E1n\u00ED je limitov\u00E1no anticholinergn\u00EDmi \u00FA\u010Dinky - p\u0159edev\u0161\u00EDm kardiotoxicitou. V indikaci l\u00E9\u010Dby diabetick\u00E9 neuropatie je registrov\u00E1no antidepresivum duloxetin. Dlouhodob\u00E9 u\u017E\u00EDv\u00E1n\u00ED antidepresiv v\u0161ak m\u016F\u017Ee zv\u00FD\u0161it riziko rozvoje diabetu 2. typu." . . . "11150" . "Epidemiologick\u00E9 studie prok\u00E1zaly, \u017Ee nemocn\u00ED s diabetem maj\u00ED zv\u00FD\u0161enou prevalenci deprese. Patogeneze deprese p\u0159i diabetu je komplexn\u00ED a zahrnuje celou \u0161k\u00E1lu p\u0159\u00ED\u010Din. Pod\u00EDlej\u00ED se na n\u00ED negativn\u00ED \u017Eivotn\u00ED ud\u00E1losti, pr\u016Fb\u011Bh a komplikace diabetu, neuroendokrinn\u00ED a neuroimunitn\u00ED zm\u011Bny, genetick\u00E9 a osobnostn\u00ED faktory. Riziko vzniku deprese u nemocn\u00FDch s diabetem mellitem je v\u011Bt\u0161\u00ED v porovn\u00E1n\u00ED se zdrav\u00FDmi lidmi, a naopak deprese m\u016F\u017Ee zvy\u0161ovat riziko rozvoje diabetu 2. typu. Kombinace diabetu a deprese m\u016F\u017Ee stup\u0148ovat riziko mortality. S depres\u00ED a diabetem tak\u00E9 souvis\u00ED v\u00FDznamn\u011B zv\u00FD\u0161en\u00E9 riziko vzniku kardiovaskul\u00E1rn\u00EDch i cerebrovaskul\u00E1rn\u00EDch poruch a demenc\u00ED. Systematick\u00E1 p\u00E9\u010De o pacienty s diabetem a depres\u00ED mus\u00ED b\u00FDt komplexn\u00ED a m\u011Bla by zahrnovat psychologickou podporu i farmakologickou l\u00E9\u010Dbu. Zvolen\u00E1 farmakologick\u00E1 l\u00E9\u010Dba by zejm\u00E9na nem\u011Bla zhor\u0161ovat kompenzaci diabetu ne\u017E\u00E1douc\u00EDmi metabolick\u00FDmi d\u016Fsledky. Vhodn\u00E1 jsou psychofarmaka ze skupiny SSRI, d\u00E1le venlafaxin a trazodon. V l\u00E9\u010Db\u011B diabetick\u00FDch pacient\u016F s depres\u00ED nepat\u0159\u00ED mezi l\u00E9ky volby tricyklick\u00E1 antidepresiva. Jejich pod\u00E1v\u00E1n\u00ED je limitov\u00E1no anticholinergn\u00EDmi \u00FA\u010Dinky - p\u0159edev\u0161\u00EDm kardiotoxicitou. V indikaci l\u00E9\u010Dby diabetick\u00E9 neuropatie je registrov\u00E1no antidepresivum duloxetin. Dlouhodob\u00E9 u\u017E\u00EDv\u00E1n\u00ED antidepresiv v\u0161ak m\u016F\u017Ee zv\u00FD\u0161it riziko rozvoje diabetu 2. typu."@cs . . "1"^^ . . . "Depression and diabetes"@en . "Depression and diabetes"@en . . "Deprese a diabetes" . "RIV/00216208:11150/14:10218516" .